BioVersys switches off bacterial drug resistance, thus reactivating approved antibiotics.
We develop small chemical molecules, which switch off drug resistance on a gene regulatory level within bacteria, so called TRIC’s (Transcriptional Regulator Inhibitory Compounds). Current pipeline: Gram negative and positive bacteria; Tuberculosis.
BioVersys plans to conduct an initial public offering on the SIX Swiss Exchange in the first quarter of 2025.
BioVersys AG announces first patient dosed in Phase 2a clinical trial with BVL-GSK099, to investigate a new treatment concept to address multidrug-resistance tuberculosis…
Building | C3 |
---|---|
Industry | Biotech |
Research Topics | Antimicrobial Resistance (AMR) |
Employees | 19 |
Founding year | 2010 |